Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Claret Bioscience specializes in innovative next-generation sequencing library preparation and analysis technologies designed to preserve the native ends of degraded DNA/RNA molecules. Their SRSLY® technology enables complex libraries from very low input cell-free DNA. Additional modules like Forshear™ improve fragmentation of genomic material while REALLY™ provides directional RNA-seq without second strand synthesis even from poor quality FFPE RNA. The company aims to empower molecular diagnostics applications such as liquid biopsy with improved understanding of nucleic acid fragments.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Claret Bioscience.